Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with once-a-day dose

Pfiz­er won’t be mov­ing a twice-dai­ly for­mu­la­tion of its oral GLP-1, danuglipron, in­to Phase III af­ter the drug trig­gered high rates of gas­troin­testi­nal side ef­fects, de­spite meet­ing the pri­ma­ry end­point of its mid-stage weight loss tri­al.

The com­pa­ny is now pin­ning its hopes on a once-dai­ly for­mu­la­tion of danuglipron, which is in Phase I stud­ies with phar­ma­co­ki­net­ic da­ta ex­pect­ed in the first half of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER